2023
Comprehensive dissection of prevalence rates, sex differences, and blood level-dependencies of clozapine-associated adverse drug reactions
van der Horst M, Meijer Y, de Boer N, Guloksuz S, Hasan A, Siskind D, Wagner E, consortium C, Müderrisoğlu A, Privat A, Bouhuis A, Hasan A, Jongkind A, Gonzalez-Pinto A, Santacana A, D'Agostino A, Ertugrul A, Yağcioğlu A, Crespo-Facorro B, Sanchez-Barbero B, Spuch C, Morgenroth C, de Pinedo C, Casetta C, Bousman C, Pantelis C, Ovejas-Catalán C, Garcia-Rizo C, Okhuijsen-Pfeifer C, Cohen D, Ristic D, Beld E, Repo-Tiihonen E, Wagner E, Jeger-Land E, Vilella E, Bekema E, Sepúlveda S, Seghi F, Wiedenmann F, Martini F, Serio F, Vairano F, Mercuriali G, Boido G, Yoca G, van Beek H, Gijsman H, Tuppurainen H, Everall I, Novakovic I, Zorrilla I, Erdoğan I, Sapienza J, Bogers J, Tiihonen J, Vázquez-Bourgon J, van Os J, Schneider-Thoma J, Luykx J, Grootens K, Mar-Barrutia L, Martorell L, Bak M, Spangaro M, de Vos M, de Koning M, Garriga M, Lähteenvuo M, Bosia M, van der Horst M, Babaoğlu M, Veereschild M, Manchia M, Edlinger M, Fuentes-Pérez P, Paribello P, Lopez-Pena P, Kahn R, Cavallaro R, Veerman S, Gutwinski S, Schreiter S, Ripke S, Baltanás T, Oviedo-Salcedo T, Hallikainen T, Görlitz T, Alink W, Ayhan Y, Okhuijsen-Pfeifer C, Luykx J. Comprehensive dissection of prevalence rates, sex differences, and blood level-dependencies of clozapine-associated adverse drug reactions. Psychiatry Research 2023, 330: 115539. PMID: 37988817, DOI: 10.1016/j.psychres.2023.115539.Peer-Reviewed Original ResearchMeSH KeywordsAntipsychotic AgentsClozapineDrug-Related Side Effects and Adverse ReactionsFemaleHumansMaleMulticenter Studies as TopicPrevalenceSex CharacteristicsWeight GainConceptsAdverse drug reactionsClinical factorsDrug reactionsPrevalence ratesCommon adverse drug reactionsWeight gainSignificant weight gainMulti-center studyImproved treatment outcomesClozapine blood levelsClozapine monotherapyClozapine treatmentLower BMIBlood levelsTreatment outcomesHigh prevalencePrevalenceMean numberYounger participantsSex differencesParticipantsTreatmentComprehensive dissectionConstipationHypersalivation
2021
Study protocol of a randomized, double-blind, placebo-controlled, multi-center trial to treat antipsychotic-induced weight gain: the Metformin-Lifestyle in antipsychotic users (MELIA) trial
de Boer N, Guloksuz S, van Baal C, Willebrands L, Deenik J, Vinkers C, Rossum I, Zinkstok J, Wilting I, Zantvoord J, Backx F, Swildens W, Schouw M, Bogers J, Hulshof F, de Knijff R, Duindam P, Veereschild M, Bak M, Frederix G, de Haan L, van Os J, Cahn W, Luykx J. Study protocol of a randomized, double-blind, placebo-controlled, multi-center trial to treat antipsychotic-induced weight gain: the Metformin-Lifestyle in antipsychotic users (MELIA) trial. BMC Psychiatry 2021, 21: 4. PMID: 33402159, PMCID: PMC7783702, DOI: 10.1186/s12888-020-02992-4.Peer-Reviewed Original ResearchMeSH KeywordsAntipsychotic AgentsDouble-Blind MethodHumansLife StyleMeliaMetforminMulticenter Studies as TopicNetherlandsQuality of LifeRandomized Controlled Trials as TopicWeight GainConceptsNetherlands Trial RegisterLifestyle interventionQuality of lifeTreatment inceptionOutcome measuresWeight gainAntipsychotic-induced weight gainSafety of metforminUse of metforminCommon adverse effectsSecondary outcome measuresPrimary outcome measureWeeks of treatmentBody weight lossMulti-center trialType 2 diabetesMajor health problemYears of ageSchizophrenia spectrum disordersTrials RegisterMetabolic syndromeOptimal management strategyExercise programMetformin treatmentDietary consultation